Andromeda Metals (ASX: ADN) Achieves 99.9989% Alumina Purity, but Can a Japanese Customer Turn the Breakthrough Into Revenue?

Producing high-purity alumina at 99.9989% purity is a significant technical milestone for Andromeda Metals Limited (ASX: ADN). Sending its first commercial sample to Japan brings the company another step towards establishing a high-value critical minerals business.

The 29 October 2026 announcement demonstrates progress in converting Great White kaolin into high-purity alumina under continuous pilot-scale conditions.

However, with only $4.3 million in cash and substantial development funding still required, the central question is whether technical success can translate into commercially sustainable earnings.

Key numbers

• 99.9989%: Highest independently verified alumina purity achieved during continuous pilot-scale production.
• 3 samples: Independently analysed, with all exceeding the 99.99% commercial 4N specification.
• $4.3 million: Cash and cash equivalents at 30 September 2026.
• $3.04 million: Gross proceeds raised through a September share purchase plan and placement.
• $1.48 billion: Pre-tax net present value estimated in the 2025 HPA Scoping Study using a 10% discount rate.

High-purity alumina breakthrough advances customer qualification

Andromeda's 29 October announcement confirmed that its continuous pilot plant had successfully produced high-purity alumina from Great White kaolin in South Australia.

Independent laboratory EAG Eurofins verified two samples at 99.9989% purity and a third at 99.9986%.

All three results exceeded the 99.99% threshold required for commercial 4N high-purity alumina.

Importantly, even a more conservative analytical calculation confirmed purity above the 4N specification.

The company has now dispatched its first commercial sample to a prospective Japanese customer operating in high-tech manufacturing.

This represents progress from technical validation towards customer qualification.

High-purity alumina is used in semiconductors, advanced ceramics, batteries and other specialised industrial applications.

However, the shipment is not a confirmed commercial order, and no binding sales agreement or revenue commitment has been disclosed.

Further customer testing will be necessary to establish product suitability, pricing and potential demand.

Continuous pilot production strengthens technical credibility

The latest results are significant because Andromeda achieved high alumina purity under continuous pilot-scale operating conditions rather than relying exclusively on laboratory experiments.

Continuous operation provides opportunities to assess processing consistency, material handling and operating performance.

These factors are important when evaluating whether the technology can eventually support larger-scale industrial production.

Andromeda is also progressing plans to manufacture both amorphous and crystalline alpha-HPA samples during the December quarter.

Different product forms could broaden potential applications and customer markets.

The company is additionally investigating amorphous silica as a possible by-product of its processing technology.

Successful recovery and commercial sale of silica could potentially improve project economics, although its financial contribution remains unproven.

Despite the encouraging results, further engineering work is required to establish commercial production costs, recovery rates and manufacturing reliability.

HPA economics offer substantial potential but remain preliminary

Andromeda's 2025 High-Purity Alumina Scoping Study outlined a potentially attractive commercial opportunity.

The study assessed a staged development targeting eventual production of approximately 10,000 tonnes of HPA annually.

It estimated a pre-tax net present value of $1.48 billion using a 10% discount rate, alongside average annual EBITDA of approximately $247 million.

These projections highlight the potential value of producing high-purity alumina from the company's kaolin resources.

However, scoping studies involve preliminary assumptions regarding production, commodity pricing, construction costs and operating expenditure.

The projected earnings should not be interpreted as established profitability or a reliable current valuation.

Further feasibility studies, engineering validation and customer qualification will be necessary before the company can establish a financeable development case.

The substantial difference between the study's projected value and Andromeda's current market valuation reflects significant uncertainty surrounding project execution, funding and future commercial demand.

Financial constraints remain a major challenge

Andromeda's September 2026 quarterly report showed cash reserves of approximately $4.3 million, compared with $3.2 million at 30 June.

The company raised approximately $3.04 million before costs through a share purchase plan and placement during September.

Operating cash outflows totalled approximately $1.36 million during the quarter, while exploration and evaluation expenditure accounted for a further $503,000.

Combined operating and exploration outflows therefore reached approximately $1.86 million.

The quarterly cash flow report indicated an estimated funding runway of approximately 2.36 quarters based on recent expenditure.

This is an indicative measure rather than a fixed deadline for additional financing, but it highlights the importance of disciplined capital allocation.

The stronger closing cash balance reflects fresh equity funding rather than internally generated operating cash flow.

Further financing may be required as Andromeda progresses customer qualification, feasibility studies and development planning.

Great White development still requires substantial funding

Alongside its HPA programme, Andromeda continues to advance the Great White kaolin project in South Australia.

The project has completed pre-construction early works and secured four binding offtake agreements supporting its proposed Stage 1A+ development.

However, the company estimates that approximately $40 million in additional equity funding remains necessary to support a final investment decision.

A previously credit-approved $75 million debt facility provides a potential financing component, although it remains subject to final approvals and documentation.

These requirements demonstrate that commercial development depends on securing substantial additional capital.

The company is also progressing discussions with Traxys North America regarding a potential five-year HPA sales agency arrangement.

The non-binding framework targets indicative annual sales of approximately 2,000 tonnes.

However, this arrangement does not represent guaranteed customer purchases or contracted revenue.

Securing binding supply agreements and credible development financing will be critical to progressing both Great White and the HPA opportunity.

Patent progress supports the technology's competitive position

Andromeda announced its first patent for its proprietary HPA processing technology on 6 October 2026.

The development strengthens its intellectual property position as the company advances technical testing and potential customer qualification.

Proprietary processing methods could provide competitive advantages if they allow Andromeda to manufacture high-purity alumina efficiently and at commercially attractive costs.

However, patent protection alone does not establish technical superiority or commercial viability.

The company must still demonstrate that its process can operate consistently at industrial scale while meeting customer specifications and cost expectations.

Successful qualification with international customers could provide further evidence of market demand and strengthen the case for future development investment.

Insight: Technical success must translate into commercial economics

What stands out to us is Andromeda's ability to produce independently verified 4N+ high-purity alumina under continuous pilot conditions while advancing its first international customer evaluation.

The 99.9989% purity result strengthens confidence in its proprietary processing technology, but product quality alone does not establish commercial competitiveness.

We believe the Japanese customer engagement and expanding intellectual property portfolio provide encouraging signs of progress towards commercialisation.

However, the company's $4.3 million cash balance and estimated 2.36-quarter funding runway underline its financial constraints.

The market may be overlooking the difference between the attractive economics projected in Andromeda's 2025 Scoping Study and the funding, construction and qualification work required to achieve them.

Our assessment would strengthen if customer testing resulted in binding supply commitments, pilot operations demonstrated competitive production costs and management secured a credible funding pathway for Great White and future HPA development.

The verdict: Technical progress strengthens the opportunity, but financing remains decisive

Andromeda has demonstrated encouraging progress through independently verified HPA purity results, international customer engagement and continued development of its proprietary processing technology.

The immediate catalysts include feedback from the prospective Japanese customer and additional HPA sample production during the December 2026 quarter.

Further pilot testing should also inform the planned HPA Pre-Feasibility Study, particularly regarding processing recoveries, operating costs and commercial scalability.

However, limited liquidity and substantial development funding requirements remain important risks.

Securing Great White's remaining equity financing and progressing the conditional debt facility will be important steps towards a final investment decision.

For shareholders, the latest purity breakthrough strengthens the technological opportunity but does not establish a profitable business.

Andromeda has demonstrated that its technology can produce exceptionally pure alumina.

The decisive challenge is proving that customers will purchase the product at prices and volumes sufficient to support a commercially viable, financeable operation.